KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Asset Utilization Ratio (2009 - 2026)

Eli Lilly posted quarterly Asset Utilization Ratio of 0.63 for Q1 2026, up 8.2% year-on-year from 0.58 in Q1 2025, and up 10.05% on a QoQ basis from 0.57 in Q4 2025.

Eli Lilly (LLY) has 18 years of Asset Utilization Ratio data on file, last reported at 0.63 in Q1 2026.

  • For the quarter ending Q1 2026, Asset Utilization Ratio rose 8.2% year-over-year to 0.63; the trailing twelve-month figure through Mar 2026 stood at 0.63 (up 8.2% YoY), and the FY2025 full-year result was 0.68, up 8.02% from the prior year.
  • Asset Utilization Ratio for Q1 2026 stood at 0.63, up from 0.57 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.63 in Q1 2026 and bottomed at 0.54 in Q1 2023.
  • The 5-year median for Asset Utilization Ratio is 0.57 (2024), against an average of 0.58.
  • The widest annual swing landed in 2022, when Asset Utilization Ratio advanced 12.35%; it then slipped 11.94% in 2023.
  • A 5-year view of Asset Utilization Ratio shows it stood at 0.59 in 2022, then retreated by 4.93% to 0.56 in 2023, then advanced by 4.28% to 0.58 in 2024, then retreated by 1.8% to 0.57 in 2025, then rose by 10.05% to 0.63 in 2026.
  • The last three Asset Utilization Ratio figures came in at 0.63 (Q1 2026), 0.57 (Q4 2025), and 0.55 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 0.63
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 0.48
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 0.46
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 0.50
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 0.41
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 0.52
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 0.12
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 0.55
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.63
Dec 31, 2025 0.57
Sep 30, 2025 0.55
Jun 30, 2025 0.56
Mar 31, 2025 0.58
Dec 31, 2024 0.58
Sep 30, 2024 0.55
Jun 30, 2024 0.57
Mar 31, 2024 0.56
Dec 31, 2023 0.56
Sep 30, 2023 0.57
Jun 30, 2023 0.55
Mar 31, 2023 0.54
Dec 31, 2022 0.59
Sep 30, 2022 0.62
Jun 30, 2022 0.62
Mar 31, 2022 0.61
Dec 31, 2021 0.58
Sep 30, 2021 0.58
Jun 30, 2021 0.56
Mar 31, 2021 0.55
Dec 31, 2020 0.54
Sep 30, 2020 0.54
Jun 30, 2020 0.55
Mar 31, 2020 0.57
Dec 31, 2019 0.58
Sep 30, 2019 0.57
Jun 30, 2019 0.57
Mar 31, 2019 0.53
Dec 31, 2018 0.49
Sep 30, 2018 0.51
Jun 30, 2018 0.52
Mar 31, 2018 0.51
Dec 31, 2017 0.52
Sep 30, 2017 0.54
Jun 30, 2017 0.56
Mar 31, 2017 0.56
Dec 31, 2016 0.56
Sep 30, 2016 0.56
Jun 30, 2016 0.58
Mar 31, 2016 0.57
Dec 31, 2015 0.56
Sep 30, 2015 0.54
Jun 30, 2015 0.55
Mar 31, 2015 0.54
Dec 31, 2014 0.55
Sep 30, 2014 0.58
Jun 30, 2014 0.61
Mar 31, 2014 0.63
Dec 31, 2013 0.67
Sep 30, 2013 0.69
Jun 30, 2013 0.70
Mar 31, 2013 0.68
Dec 31, 2012 0.66
Sep 30, 2012 0.69
Jun 30, 2012 0.73
Mar 31, 2012 0.73
Dec 31, 2011 0.73
Sep 30, 2011 0.74
Jun 30, 2011 0.74
Mar 31, 2011 0.74
Dec 31, 2010 0.75
Sep 30, 2010 0.78
Jun 30, 2010 0.82
Mar 31, 2010 0.81
Dec 31, 2009 0.93
Sep 30, 2009 0.91